Shielding Global Health: Pneumococcal Vaccines Market Poised to Surpass US$ 13.3 Billion by 2033

The pneumococcal vaccines market stands as a pivotal contributor to global health, offering a powerful tool to combat infections caused by Streptococcus pneumoniae bacteria. These bacteria are responsible for a range of illnesses, including pneumonia, meningitis, and sepsis, posing a significant threat, especially to young children, the elderly, and individuals with weakened immune systems. Pneumococcal vaccines have emerged as a cornerstone of preventive healthcare, driving down disease burdens, hospitalizations, and mortality rates.

The essence of the pneumococcal vaccines market lies in its ability to prevent life-threatening infections. By stimulating the immune system to recognize and attack the Streptococcus pneumoniae bacteria, these vaccines drastically reduce the risk of developing severe illnesses. This is particularly crucial for vulnerable populations, such as infants and older adults, who are at higher risk of complications due to their weaker immune responses.

Accelerate Your Journey to Excellence with Unmatched Efficiency! Claim Your FREE Sample Now :
https://www.futuremarketinsights.com/reports/sample/rep-gb-7078

During the forecast period, the global pneumococcal vaccines market is expected to grow at a 4.1% CAGR. In 2023, the market is currently valued at US$ 8.9 billion. The pneumococcal vaccines market is expected to exceed a market valuation of US$ 13.3 billion by 2033. Future Market Insights analysts recorded a historical market valuation of US$ 8.5 Billion for the concerned market during the base year.

FMI has analyzed that due to the growth of the geriatric population the prevalence of pneumococcal disease is surging at a robust pace. This factor is the key stimulant behind the growth of the pneumococcal vaccine market. A major section of the urban population is inclined towards consuming tobacco and alcohol, which is leading to pneumococcal disorders like bloodstream infections, meningitis, bacteremic pneumonia, and more. Therefore, the pneumococcal vaccines market is estimated to propel at a robust pace through 2033.

Additionally, the government across the developing regions is taking initiative to create awareness about bacterial pneumonia and is extending grants to the public authorities for the treatment of the same. This element prevailing in the market is likely to stir up the market landscape of pneumococcal vaccines in the long run.

Key Takeaways from the Pneumococcal Vaccines Market :

• The pneumococcal vaccines market has witnessed an unprecedented surge of US$ 0.4 Billion from the base year to the current.
• The pneumococcal vaccines market is estimated to advance forward at a moderate pace, registering a CAGR of 4.1% through the forecast period.
• The Prevenar-13 segment by product type category has accounted for the highest share of the pneumococcal market with US$ 9,500 Million in 2023.
• The public authorities segment by distribution channel category is estimated to hold dominant shares, trailing at a CAGR of 6.8% through the projection period.

“Rising disposable income and a growing population of patients, coupled with initial investments received from the government is likely to curate lucrative growth prospects for the pneumococcal vaccine manufacturers.” – Says an FMI Analyst.

Personalize Your Report for a Competitive Advantage in the Pneumococcal Vaccines Market :
https://www.futuremarketinsights.com/customization-available/rep-gb-7078

Competitive Landscape in the Pneumococcal Vaccines Market :

The manufacturers in the pneumococcal vaccines market are indulging in activities that would fuel the rapid advancement of the industry through the forecast period. They are collaborating and entering into strategic partnerships with other prominent players proliferating in the market. Additionally, they are making significant investments in research and development activities to further launch products with advanced curing rates. They are entering into mergers and acquisitions to further strengthen their foothold in the market.Panacea Biotech Ltd, Pfizer Inc, Sanofi S.A, Walvax Biotechnology Co. Ltd, and CSL Ltd are some of the key players in the market.

Recent Developments :

• In September 2020, a Japanese pharmaceutical company, Shinogi, made an announcement to enter into a license agreement with Hanavax, a next-generation nasal vaccine manufacturer. The agreement was likely to assist the company in research and development activities, commercialization, manufacturing, and distribution of Streptococcus pneumonia vaccines developed by Hanavax.
• In December 2019, China-based biotechnology company, Walvax Biotechnology Co., Ltd. received approval from the regulatory body of China, the National Medical Products Administration for its pneumococcal-13 valent conjugate vaccine. This vaccine is also estimated to act as an alternative to Prevnar-13 for immunizing children in the age group of 6 months to 5 years.
• In January 2018, Pfizer, one of the global leaders in the pharmaceutical industry made an announcement to reduce the price of the PCV-13 4-dose vial vaccine from US$ 3.05 to US$ 2.95 per dosage in the Gavi-supported countries.

Curious? We’ve Got Answers! Unleash Your Questions and Uncover the Knowledge You Seek – Ask Us Anything Today :
https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-7078

Key Segments in the Pneumococcal Vaccines Market

By Product Type:

• Pneumococcal Polysaccharide Vaccines
• Pneumococcal Conjugate Vaccines

By Distribution Channel:

• Pharmacies
• Community Clinics
• Public Health Agencies
• Others

About Future Market Insights (FMI):

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favour the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10 years.

Contact Us:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

LinkedIn | Twitter | Blogs | YouTube

For Sales Enquiries: sales@futuremarketinsights.com